UZL
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vergote, Ignace B
INNOVATE-3, NCT03940196: Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / )

Completed
3
540
Europe, Canada, US, RoW
NovoTTF-100L(O), TTFields, Paclitaxel, Weekly Paclitaxel, Taxol
NovoCure Ltd.
Ovarian Cancer
05/23
05/23
NCT02822157 / 2015-005838-22: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Active, not recruiting
2
160
Europe
Olaparib, Lynparza, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Universitaire Ziekenhuizen Leuven, AstraZeneca
Ovarian Epithelial Cancer
07/21
07/23
NCT03340376 / 2016-000547-14: Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting
2
48
Europe
Atezolizumab, Doxorubicin
Universitaire Ziekenhuizen KU Leuven, Roche Pharma AG
Cervical Cancer
09/25
09/25

Download Options